

CO-CHAIR & PRESENTER
Jerome A. Barakos, MD

CO-CHAIR & PRESENTER
Tammie L.S. Benzinger,
MD, PhD

PeerView
Live

CME/AAPA

Improving the Recognition and Management of Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer's Disease Treatment

Practical Tools & Strategies for Radiology & Neuroradiology Specialists

 Wednesday, May 28, 2025

 6:30pm to 7:30pm PDT

 Zoom - [Click here to Register](#)

 Ana M. Franceschi, MD, PhD

Associate Professor of Radiology

Director of Dementia Imaging

Director of Molecular Neuroimaging

Donald and Barbara Zucker School of Medicine at
Hofstra/Northwell

Lenox Hill Hospital, New York, New York

Activity Description

Alzheimer's disease (AD) is a devastating and highly prevalent condition, affecting 10% of people over 65 years of age and increasing as the population ages. Given the heavy economic and social burdens of AD, major emphasis has been placed on finding disease-modifying therapies (DMTs) that can address the underlying pathophysiology and prevent, delay, slow, or halt the inexorable decline of AD.

Now, after almost two decades without a new AD treatment, several recent advances in DMTs—including the FDA approvals of two amyloid-targeting therapies (ATTs) and a third in late-stage development—have opened the door to the possibility of reductions in disease progression and improved patient outcomes. This policy change will greatly expand the number of individuals who may be treated with ATTs.

Amyloid-related imaging abnormalities (ARIA) are common side effects of treatment with ATTs. While serious adverse events due to ARIA are rare, there have been multiple case reports of patients who had to be hospitalized due to brain swelling, seizures, epileptiform activity, malignant hypertension, encephalopathy, and pronounced worsening on mental status exams.


In order to aid clinicians in identifying and managing severe ARIA, PeerView has prepared a collection of virtual, in-person, and on-demand workshops. Our expert faculty will review MRI protocols and ARIA grading scales to detect, interpret, and monitor for ARIA, as well as how to communicate relevant ARIA findings to referring clinicians and other members of the care team.

Educational Objectives

Upon completion of this activity, participants should be better able to:

- Implement evidence-based MRI protocols and guideline-directed ARIA grading scales to facilitate the detection, interpretation, and monitoring of ARIA-E and ARIA-H
- Utilize an ARIA reporting template to facilitate timely and clear communication of relevant ARIA findings to the referring clinicians and other members of the care team to optimize patient management

Accreditation, Support, and Credit

 In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

 PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.